Drug Trial Radar · NCT07298421
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Aug 18, 2026
Primary completion
May 31, 2030
Study completion May 30, 2031
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III, double-blind, multi-center treat-through study will evaluate the efficacy and safety of Afimkibart (also known as RO7790121) in children with moderately to severely active Crohn's Disease (CD).
Conditions
- Moderately to Severely Active Crohns Disease
Interventions
AfimkibartDrug
Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Clinical Remission per Pediatric Crohn's Disease Activity Index (PCDAI)Time frame: At Week 52
- Percentage of Participants With Endoscopic ResponseTime frame: At Week 52
Locations
19 sites in 8 countries. Site status is shown where the registry gives one.
NYU Langone Health
New York, New York · Recruiting
Texas Digestive Specialists
Harlingen, Texas · Recruiting
Mater Hospital Brisbane
South Brisbane, Queensland, Australia · Recruiting
Royal Children's Hospital
Parkville, Victoria, Australia · Recruiting
Perth Children's Hospital
Nedlands, Western Australia, Australia · Recruiting
Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
CECIP - Centro de Estudos Clínicos do Interior Paulista
Jaú, São Paulo, Brazil · Recruiting
BR Trials - Pesquisa Clínica
São Paulo, São Paulo, Brazil · Recruiting
FAICIC Clinical Research
Veracruz, Mexico · Recruiting
Centro de Investigación Clínica Acelerada, S.C
Mexico City, Mexico CITY (federal District), Mexico · Recruiting
IATROS International
Bloemfontein, South Africa · Recruiting
Emmed Research
Pretoria, Gauteng, South Africa · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Chulalongkorn University
Bangkok, Thailand · Recruiting
Siriraj Hospital
Bangkok, Thailand · Recruiting
Ramathibodi Hospital
Bangkok, Thailand · Recruiting
Birmingham Children's Hospital
Birmingham, United Kingdom · Recruiting
King's College Hospital
London, United Kingdom · Recruiting
Sheffield Childrens Hospital
Sheffield, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.